Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer

For men with metastatic non-castrate prostate cancer with high volume disease per CHAARTED who are candidates for treatment with chemotherapy, the addition of docetaxel to ADT should be offered. (EB, H, S)

For patients with low volume disease per CHAARTED who are candidates for chemotherapy, docetaxel plus ADT may be offered. (EB, H, M)

The appropriate regimen of docetaxel is six doses of docetaxel given every three weeks at 75 mg/m2 either alone (per CHAARTED) or with prednisolone (per STAMPEDE). (EB, H, S)